Skip to content
Search

Latest Stories

Apple’s ‘private relay’ privacy feature not available in China

APPLE’S newly introduced privacy protection feature, ‘private relay’ will not be available to users in China due to regulatory reasons.

At its annual software developer conference, Apple announced a set of new privacy protections including a function called "private relay", where users' web browsing behaviour can be hidden from Apple, internet providers and advertisers.


The feature could not be rolled out in China, as the internet is closely controlled there, along with an extensive surveillance system of its residents.

China is a key market for Apple and accounts for 15 per cent of its revenue.

The tech giant has been under pressure to cut down on the tracking of user data.

The new function will not be available in several other countries, including Saudi Arabia, Belarus, South Africa and Kazakhstan.

Explaining the new function, Apple said this feature sends traffic to a server maintained by Apple, where its IP address will be removed.

From there, it goes to a second server operated by a third party, where a temporary IP address is generated and sent onto the destination website.

According to technology experts, the function will prevent advertisers from using IP addresses to pinpoint a person's location.

Apple also introduced new privacy features included in the latest iPhone operating system, iOS 15, that will allow users to track which apps are collecting data.

Users will also be able to block tracking with apps like Mail.

The new features are likely to hinder social media companies like Facebook, Google and Twitter as customised advertising is central to their business model.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less